Loading clinical trials...

Reduction Of Dietary Salt Intake To Control Systolic Blood Pressure In Hypertensive Older Patients | Clinical Trials | Clareo Health

UNKNOWNNA

Reduction Of Dietary Salt Intake To Control Systolic Blood Pressure In Hypertensive Older Patients

Reduction Of Dietary Salt Intake To Control Systolic Blood Pressure In Hypertensive Older Patients: The Repress Randomized Controlled Trial

NCT05976477•Mario Negri Institute for Pharmacological Research

View on ClinicalTrials.gov

Summary

REPRESS is an open label, pragmatic, multicenter, randomized controlled phase III trial with blinded endpoint with 1:1 (intervention to control arm) allocation ratio. The REPRESS trial is aimed to determine the efficacy of an educational intervention aimed at reducing dietary salt intake in elderly people (60+) with moderate hypertension and exposed to polypharmacy (3+ drugs) in improving systolic BP control compared to an attention arm.

Eligibility

Age

60 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Community-dwelling patients aged ≥60 years;
•2. Prescribed ≥3 drugs;
•3. A) Systolic blood pressure ≥130 and ≤160 mmHg for patients prescribed stable antihypertensive therapy (at least 1 drug (ATC code: C02\*, C03\*, C07\*, C08\*, C09\*)); B) Systolic blood pressure ≥140 and ≤160 mmHg for those patients not prescribed any antihypertensive drug;
•4. Capable of feeding independently;
•5. Own a smartphone;
•6. Frequently consuming home-cooked meals (≥4 days during a week and ≥3 during the weekend per month);
•7. Giving signed informed consent.

Exclusion Criteria

•1. Living in a nursing home or having applied for nursing home admission;
•2. Being prescribed (adding, switching or changing dosage) an antihypertensive drug in the three months before enrollment;
•3. Undergoing renal replacement therapy with dialysis or having renal impairment with estimated glomerular filtration rate (eGFR) \<25 mL/min/1.73 m2 (assessed by CKD-EPI formula) \[30\] within previous six months or at the screening assessment;
•4. Following a low-sodium dietary regimen;
•5. Being unable or refusing to sign informed consent.

Key Dates

Start Date

October 1, 2023

Primary Completion Date

June 30, 2025

Completion Date

December 31, 2025

Last Updated

September 1, 2023

Enrollment

266

ESTIMATED participants

Conditions

Hypertension

Interventions

educational intervention

OTHER

Contacts

Carlotta Franchi

CONTACT

+39 02 39014580 carlotta.franchi@marionegri.it

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITING

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

NCT07480265

Hypertension (HTN)Hyperhomocysteinemia+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 1, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Reduction Of Dietary Salt Intake To Control Systolic Blood Pressure In Hypertensive Older Patients

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets